IGF-1 LR3 (1mg)

Introduction

IGF-1 LR3 is a recombinant peptide analog derived from human insulin-like growth factor-1 (IGF-1) with a 13–amino acid extension at the N-terminus and a substitution of arginine at position 3. These modifications inhibit binding to IGF-binding proteins (IGFBPs), significantly increasing the peptide’s half-life and receptor activity. In laboratory settings, IGF-1 LR3 is studied for its involvement in cellular proliferation, differentiation, and survival—key pathways in metabolic, endocrine, and regenerative research.

---

Stability and Bioavailability

Compared to native IGF-1, IGF-1 LR3 demonstrates enhanced stability in cell culture and serum environments. Its structural modification reduces IGFBP interference, resulting in prolonged receptor engagement and increased biological potency. This allows researchers to study long-term IGF-1 receptor–mediated processes with consistent molecular activity and reproducible outcomes.

---

Research Applications

Cellular Growth and Differentiation

IGF-1 LR3 stimulates cell proliferation and differentiation across a variety of tissue types, including muscle, bone, and neural cells. It is used in studies evaluating anabolic signaling, protein synthesis, and stem cell development.

Metabolic and Endocrine Function

By mimicking endogenous IGF-1 signaling, IGF-1 LR3 aids in exploring the metabolic effects of insulin-like peptides, including glucose utilization, lipid metabolism, and endocrine regulation. It also serves as a reference peptide in insulin sensitivity assays and growth factor cross-talk studies.

Tissue Repair and Regeneration

Due to its role in activating the PI3K/Akt pathway, IGF-1 LR3 has been investigated for its capacity to promote cellular repair and reduce apoptosis in in-vitro models of tissue injury. Researchers use it to study growth factor–driven wound healing and tissue regeneration mechanisms.

---

Summary

IGF-1 LR3 is a potent and stable analog of insulin-like growth factor-1 that extends receptor signaling duration and minimizes IGFBP inhibition. It continues to serve as a cornerstone compound for understanding growth factor biology, anabolic metabolism, and cellular regeneration.

---

References

1. Clemmons DR, Metabolic actions of IGF-I in normal physiology and diabetes, Endocrinology and Metabolism Clinics of North America (2012). PubMed

2. Schedlich LJ et al., TGF-β-induced expression of IGFBP-3 regulates IGF1R signaling in human osteosarcoma cells, Molecular and Cellular Endocrinology (2013). PubMed

3. Xu J et al., Biological effects of IGF-1 and its analogs on cell growth and apoptosis, Molecular and Cellular Endocrinology (2004). https://doi.org/10.1016/j.mce.2004.02.018

4. Le Roith D et al., Insulin-like growth factors in pediatric health and disease, The Journal of Clinical Endocrinology and Metabolism (1999). PubMed

 

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.